Zhu, Tong
Moy, Selina
Valluri, Udaya
Cao, Ying
Zhang, Wenhui
Sawamoto, Taiji
Chindalore, Vishala
Akinlade, Bola
Funding for this research was provided by:
Astellas Pharma Global Development
Article History
First Online: 26 June 2020
Compliance with Ethical Standards
:
: Peficitinib is approved in Japan, Korea, and Taiwan for the treatment of rheumatoid arthritis. Astellas Pharma Global Development Inc. funded this study. Editorial assistance with manuscript development was funded by Astellas Pharma Inc.
: Tong Zhu, Udaya Valluri and Ying Cao are employees of Astellas Pharma Global Development Inc. Wenhui Zhang was an employee of Astellas Pharma Global Development Inc. at the time of the study. Selina Moy is an employee of Astellas Research Institute of America. Taiji Sawamoto is an employee of Astellas Pharma Inc. Bola Akinlade was an employee of Astellas Pharma Global Development Inc. at the time of the study, and is now an employee of Regeneron Pharmaceuticals; he reports no conflicts of interest that are directly relevant to the content of this study. Vishala Chindalore is an employee of Pinnacle Research Group/Anniston Medical Clinic, which received funding from Astellas to conduct the study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board for the study site (Quorum Review Institutional Review Board, Seattle, WA, USA) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Researchers may request access to anonymized participant-level data, trial-level data and protocols from Astellas-sponsored clinical trials at ExternalRef removed. For the Astellas criteria on data sharing, see ExternalRef removed.